Literature DB >> 11033554

Prevention of infection with tobramycin-containing bone cement or systemic cefazolin in an animal model.

M W Nijhof1, H P Stallmann, H C Vogely, A Fleer, L M Schouls, W J Dhert, A J Verbout.   

Abstract

We investigated in an animal model the efficacy of tobramycin-containing bone cement and systemic cefazolin for infection prophylaxis. In 18 female rabbits, the femoral cavity was inoculated with Staphylococcus aureus before injection of bone cement. The first group of six rabbits received tobramycin-containing Simplex-P bone cement. Two other groups of six rabbits received plain Simplex-P bone cement. Preoperatively, in one of the two latter groups cefazolin was administered intravenously. The other group served as untreated controls. The rabbits were monitored for clinical signs of infection. At 7 days' follow-up, the femora were harvested and cultures from the bone adjacent to the cement plug were quantified. Cultures from the rabbits which received antibiotic prophylaxis (either cefazolin systemically or tobramycin-containing bone cement) were all negative. In contrast, all rabbits in the untreated control group had positive cultures. These rabbits also had other signs of infection such as an elevated erythrocyte sedimentation rate and loss of body weight. Culture results were confirmed by the absence of bacterial DNA in the polymerase chain reaction hybridization assay. In conclusion, we found that both tobramycin-containing bone cement and systemic cefazolin are effective in preventing implant bed infection in rabbits up to 7 days after contamination with S. aureus. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033554     DOI: 10.1002/1097-4636(20001215)52:4<709::aid-jbm16>3.0.co;2-w

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  5 in total

Review 1.  A systematic review of animal models for Staphylococcus aureus osteomyelitis.

Authors:  W Reizner; J G Hunter; N T O'Malley; R D Southgate; E M Schwarz; S L Kates
Journal:  Eur Cell Mater       Date:  2014-03-25       Impact factor: 3.942

2.  In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile.

Authors:  Hein P Stallmann; Chris Faber; Antonius L J J Bronckers; Arie V Nieuw Amerongen; Paul I J M Wuisman
Journal:  BMC Musculoskelet Disord       Date:  2006-02-26       Impact factor: 2.362

3.  The longitudinal assessment of osteomyelitis development by molecular imaging in a rabbit model.

Authors:  Jim C E Odekerken; Geert H I M Walenkamp; Boudewijn T Brans; Tim J M Welting; Jacobus J C Arts
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

4.  Prophylactic Effects of NFκB Essential Modulator-Binding Domain Peptides on Bone Infection: An Experimental Study in a Rabbit Model.

Authors:  Wen-Jiao Wu; Chang-Liang Xia; Shuan-Ji Ou; Yang Yang; Xiao-Zhong Zhou; Yun-Fei Ma; Yi-Long Hou; Fa-Zheng Wang; Qing-Po Yang; Yong Qi; Chang-Peng Xu
Journal:  J Inflamm Res       Date:  2022-04-28

5.  Efficacy of NEMO-binding domain peptide used to treat experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus: an in-vivo study.

Authors:  Chang-Peng Xu; Ya Chen; Hong-Tao Sun; Zhuang Cui; Ya-Jun Yang; Lei Huang; Bin Yu; Fa-Zheng Wang; Qing-Po Yang; Yong Qi
Journal:  Antimicrob Resist Infect Control       Date:  2019-11-20       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.